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How are viruses released from a cell?
Basic research projects often involve narrow,
focused aspects of basic processes. One such
piece is the process by which certain viruses
move from one cell to then spread and infect
additional cells.
To replicate, viruses turn host cells into
“virus factories.” The new viruses then move
on to infect other cells and the whole process
begins again. The mechanism that allows a
virus to be released efficiently from one cell
and move to another is the main interest of
Ronald Harty’s laboratory at the School.
Viruses are released from a cell though a
process called budding. The virus pushes the
lipid membrane of the cell outward so that it
enfolds the virus. This budding virus separates
from the cell and the new virus particle is ready
to infect the next cell.
The mechanism that governs this process is
not well understood and scientists have been
trying to understand this process of budding as
it could help in combating viral diseases. Dr.
Harty, assistant professor of microbiology, and
his colleagues, two years ago identified a
sequence of amino acids that is instrumental in
the movement of Ebola virus out of a cell. “We
discovered a short sequence of four amino
acids contained in the matrix protein of Ebola
virus that is instrumental to budding,” says Dr.
Harty. “If this sequence or motif, as it is called,
is changed, the budding process slows down
significantly.”
This motif not only is present in the matrix
protein of the Ebola virus, but also in the
matrix proteins of vesicular stomatitis virus
(VSV) and HIV. All three viruses are RNA
viruses with different characteristics and they
represent three different virus families: Ebola is
a filovirus, one of the biggest viruses; VSV is
rhabdovirus, this family includes rabies; HIV is
a retrovirus. The motif is interchangeable
between these different virus groups, such that
the motif from one initiates budding in
another group when implanted in that matrix
protein.
“We have found that budding occurs if we
move the motif from one place to another on
the matrix protein,” says Harty. “The protein by
itself also causes budding. It is thought that the
motif interacts with specific cellular proteins
for budding to occur. We are trying to identify
these cellular proteins. Because budding doesn’t
completely cease if the amino acid sequence of
the motif is changed, we know other interac-
tions are involved in the process.”
Most of the work in the laboratory occurs
with VSV, a RNA virus with an RNA genome
of about 11,000 bases, considerably smaller
than the Ebola virus genome of 19,000 bases.
VSV, a reportable disease, afflicts cattle and
equines. Symptoms in cattle resemble foot and
mouth disease and animals must be quaran-
tined until an accurate diagnosis is made.
“Although we work with VSV, we do not work
with actual Ebola virus, just with DNA plas-
mids that make the proteins we are studying,”
says Harty. “These plasmids are just pieces of
DNA that are not infectious. We could not
work with Ebola virus or any other lethal virus
as that requires the highest grade secure labora-
tory which we do not have.”
The members of Dr. Harty’s laboratory
working on the Ebola virus project are Jill
Licata, Ph.D. student and Dr. Ziying Han, a
post doc. Recently, Dr. Harty and Dr. Bruce
Freedman, V’87, assistant professor of pathobi-
ology, received a NIH grant to examine Ebola
virus proteins that may have channel activities
in the cell during budding. These may well be
another piece needed in the budding process. It
may bring scientists closer to a means that can
prevent the spread of virus from cell to cell. Dr.
Harty’s research on the amino acid motifs is
also supported by a second NIH grant.
infection; 30-40% of cats in the NE are carriers
for the infection) that they could not overcome
because they were immunocompromised.
“Right now we give cyclosporine and pred-
nisolone to our transplant patients to prevent
rejection of the new kidney,” explains Aronson.
“Unfortunately, long term use of these immune
system suppressing drugs can make a patient
more susceptible to infection and cancer. This
has been seen in people and we have also seen
it in our transplant patients.”
The new drug, CTLA4-Ig, is being used in
clinical trials in human transplant patients. It is
hoped that it does not have the long-term effects
of the drugs currently used. “The drug has been
shown to prevent rejection in many research
models. Hopefully, its more specific mechanism
of action will allow a patient to respond to an
infection as well.” says Aronson. “We are now
investigating the drug in vitro to determine its
effect on feline lymphocytes, a group of infec-
tion-fighting cells. It appears that the drug sup-
presses feline lymphocyte proliferation, but
allows some cells to remain intact. Some of the
cells that remain intact appear to be cells (mem-
ory cells) that have previously seen the infectious
agent and are present to respond to the infec-
tious agent again. Eventually, we have to deter-
mine if the degree of immunosupression seen in
vitro using CTLA4-Ig is enough to prevent rejec-
tion in an in vivo model.”
Aronson hopes the drug will provide an
alternative to cyclosporine and prednisolone so
that her feline transplant recipients remain able
to suppress a latent toxoplasmosis infection and
fight of any other infections.
Mason is looking at another factor involved
in the immune response to Toxoplasma gondii.
In Hunter’s lab, she is studying the role of c-
Rel, a gene that controls the production of the
cytokines interferon gamma (IFN-g) and Inter-
leukin 12 (IL-12), both essential for resistance
to toxoplasma infections.
“The cytokines are important in resistance to
toxoplasmosis,” says Mason.“We are studying the
immune response to toxoplasma in mice that
lack the c-Rel gene. When these mice are infected
with Toxoplasma gondii, their resistance to the
disease is very low. They have normal levels of IL-
12 and reduced levels of IFN-g early on during
infection. This may allow the parasite to establish
itself in the mouse and result in a reduced sur-
vival time compared to wild type mice.”
To know the role the gene c-Rel plays in the
immune response is important as this gene is
also involved in producing resistance to Leish-
mania, another protozoan disease that is dev-
asting to people and animals, and to viral infec-
tions. Once this role is completely understood,
scientists may be able to develop treatments
that reinforce c-Rel and help people and ani-
mals overcome these infectious diseases.
Aronson and Mason are just two clinicians
at the School who are taking advantage of the
proximity of the basic scientists to the clinical
facilities; there are many more clinicians, at
VHUP and at New Bolton Center, who work
closely with bench scientists, incorporating
basic science findings into clinical applications.
